You cannot copy content of this website, your IP is being recorded
GLP-1 Medication Patient Care

GLP-1 Patient Care for Diabetic Weight Management and Metabolic Health Weight Management in Jamestown, and Fargo, ND

GLP-1 agonist may be prescribed by medical practitioners to help patients lose weight. These medications can also help to reduce appetite, create insulin efficiency and overall improved metabolism. To begin your weight loss journey and to see if you qualify for a GLP-1 medication or to renew a GLP-1 medication through Medallus Medical, please fill out this form. You also may contact us or see our business hours online. We have convenient locations to serve you in Jamestown ND and Fargo ND.

GLP-1 Patient Care for Diabetic Weight Management and Metabolic Health Weight Management in Jamestown, and Fargo, ND
GLP-1 Patient Care for Diabetic Weight Management and Metabolic Health Weight Management in Jamestown, and Fargo, ND

What does GLP-1 mean?

GLP-1 (Glucagon Like Peptide-1) is an incretin hormone produced by the L cells in the intestine in response to food intake.

What is a peptide?

A peptide is a naturally occurring chemical made up of two or more amino acids linked by peptide bonds. They’re crucial in nature and biochemistry, with thousands found naturally in humans and animals. Peptides are created both naturally and synthetically, and they’re categorized based on the number of amino acids they contain.

Why are GLP-1 medications effective for helping diabetic patients and for weight management?

GLP-1 medications (peptides) help regulate glucose and insulin through more efficient cell signaling in the intestine.

  • GLP-1 receptor agonists are medications that imitate the action of GLP-1, aiding your body in using GLP-1 and insulin effectively to maintain stable postprandial blood sugar levels.
  • GLP-1 receptor agonists can help you feel full after eating.
  • People often find themselves effortlessly cutting calories, leading to easier weight loss.

The two primary GLP-1 peptide medications used for assisting diabetic patients and for weight management are semaglutide and tirzepatide.

GLP-1 Agonism

  • Both semaglutide and tirzepatide primarily target the GLP-1 receptor, enhancing its activity.
  • GLP-1 regulates glucose homeostasis and insulin secretion.

Semaglutide is a GLP-1 receptor agonist:

  • Semaglutide is primarily used for the treatment of type 2 diabetes mellitus, helping to control blood sugar levels by stimulating insulin release.
  • Semaglutide is indicated for adults with type 2 diabetes who require better glycemic control, either as a standalone treatment or in combination with other diabetes medications.
  • Side Effects: Burping, nausea, vomiting, and constipation are common side effects of semaglutide.

Tirzepatide stands out by being both a GLP-1 and GIP agonist:

  • GIP is another incretin hormone that enhances insulin secretion in a glucose-dependent manner.
  • Dual Agonism: Tirzepatide’s dual agonism of GLP-1 and GIP can offer a more comprehensive approach to glucose control than semaglutide.
  • Improved Glucose Control: Tirzepatide enhances glucose-dependent insulin secretion for better blood sugar regulation.
  • Weight Management: The dual action may contribute to better weight management.
  • Clinical Implications: broader glycemic control – tirzepatide may be especially beneficial for patients requiring extensive glycemic control.
  • Individualized Treatment: understanding the mechanisms allows tailored treatment plans.
  • Side Effects Common side effects of tirzepatide may include nausea, vomiting, and the risk of pancreatitis. Many patients report that they have lessened gastrointestinal side effects as compared to semaglutide.

Weight Management Results:

Semaglutide: A double-blind, randomized controlled trial comparing semaglutide 2.4 milligrams once weekly given subcutaneously to placebo was conducted. It enrolled just under 2,000 patients without type 2 diabetes and, similarly, with a BMI of at least 30 or of at least 27 with at least one weight-related coexisting condition. Both groups received lifestyle intervention. After 68 weeks, patients in the semaglutide group lost a mean of 14.9% of their body weight, compared to 2.4% in the placebo group.

Tirzepatide: It was reported that a third of patients lost at least 25% of their starting body weight (over 58 lbs, while taking the highest tirzepatide dose (15 mg per week).

Glucose Homeostasis Success with Glucagon-Like-Peptide (GLP-1)

  • Improves pancreatic activity to control blood sugar levels
  • Improves glucose uptake in skeletal muscle to burn fat
  • Improves intestine movement by propelling food intake more efficiently
  • Reduces appetite through serotonin and the effectiveness of metabolism
  • Cardioprotective effect through body weight reduction, improved glycaemia, blood pressure, reduced risk of atherosclerosis and inflammation
  • Reduces liver enzymes that cause nonalcoholic fatty liver disease
  • Minimizing Neurodegenerative Disease-Retinal repair, Alzheimer’s disease, Dopamine (DA) levels in Parkinson’s disease and overall reduction of cognitive impairment

GLP-1 Positive Physiological and Therapeutic Effects:

  • Human brain
  • Pancreas
  • Heart
  • Gastrointestinal tract (GI tract) and Liver

What do GLP-1 medications cost?

It is recommend you do your research for GLP-1 Manufacture Pricing and Manufacture Coupons

What do professional services or counselling for diabetic or anti-obesity cost?

GLP-1 503 A Compounded Pharmacy Semaglutide or Tirzepatide

What is compounded semaglutide or tirzepatide?

Compounded semaglutide or tirzepatide is a patient-specific medication created in a state Board of Pharmacy or FDA licensed compounding facility per a prescription from a licensed healthcare professional. Compounded drugs must use ingredients solely from FDA-licensed facilities and test sterile compounds for potency, sterility, and purity.

Medallus Medical Clinic providers prescribe through state Board of Pharmacy or FDA licensed sterile compounding pharmacies in the United States.

GLP-1 Medication Patient Care Process

Step 1: Contact Us
Call our clinic directly or connect with us online.

Step 2: Patient Registration

Step 3: Evaluation
Qualifying Evaluation and Criteria:

  • Patients with a BMI 27-29 with a weight related comorbidity i.e., Hypertension, sleep apnea, diabetes mellitus type 2, coronary artery disease, hyperlipidemia, osteoarthritis, gastroesophageal reflux disease, body pain and difficulty with physical functioning directly related to being overweight, and/or insulin resistance defined by a fasting insulin level of 7 uIU/ml or above.
  • Patients with a BMI >30


  • Allergy to semaglutide or tirzepatide, any GLP-1 agonists, or compounded components
  • H of Medullary Thyroid Carcinoma (MTC) in the individual or family
  • Multiple endocrine neoplasia Type 2
  • BMI <27 (to start)
  • Diabetes mellitus type 1 or Insulin dependent type 2
  • Type 2 Diabetics with a written note from their primary care physician or endocrinologist may qualify however, final approval will be at the discretion of the clinical practitioner
  • Patients taking medications typically prescribed for Diabetes Mellitus
  • Current Pancreatitis
  • Active gallbladder disease
  • Kidney disease – stage 2 or higher
  • Chronic or persistent hypoglycemia with ranges <60mg/dl
  • Pregnancy
  • Breast Feeding
  • <18 years of age

Step 4: Telehealth Consultation
Confirm patient results and order the prescriptions.

Telemedicine Visit at Medallus Urgent Care

Locations to Medallus Urgent Care

Jamestown, ND

Fargo, ND

Directions to Nearest Location